Exchange: NASDAQ·Updated 04:41 PM EST

VRAX News

News
all
press releases
Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland ChinaPR NewswireLONDON, Oct. 29, 2026 Three new distributor agreements build on initial China sales and extend the...
PR Newswire
Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland ChinaPR NewswireLONDON, Oct. 29, 2026 Three new distributor agreements build on initial China sales and extend the...
PR Newswire
More News
No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.
Stocktwits
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement PR...
PR Newswire
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds PR Newswire LONDON, July 10, 2026 LONDON, July 10, 2026...
PR Newswire
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds PR Newswire LONDON, July 9, 2026 LONDON, July 9, 2026 /PRNewswire/ -- Virax...
PR Newswire
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences (NASDAQ:FBRX) stock roseread more...
Benzinga
A wave of corporate announcements, from international distribution agreements and manufacturing leadership appointments to expanding government contracts and enterprise AI initiatives, several companies confirm strengthening revenue opportunities and long-term execution. $BLIS, $VRAX, $ENVX, $RKTO, $SPCX, $TDTH
24-7 Market News
Virax Biolabs (NASDAQ:VRAX) has taken a meaningful step from product development toward commercial execution by signing an exclusive multi-country commercial supply agreement with Fosun Diagnostics, one of Asia's largest diagnostics organizations. While still an emerging biotechnology company, Virax is now positioned to begin generating near-term revenue from its commercially available ImmuneSelect research-use product line while continuing to develop its flagship ViraxImmune diagnostic platform.
24-7 Market News
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stockread more...
Benzinga
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics PR Newswire LONDON, July 9, 2026 LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the...
PR Newswire

Advertisement|Remove ads.